Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis

摘要

IntroductionWidespread use of ten-valent (Synflorix?, GSK) or 13-valent (Prevenar 13?; Pfizer) conjugate vaccination programs has effectively reduced invasive pneumococcal disease (IPD) globally. However, IPD caused by serotypes not contained within the respective vaccines continues to increase, notably serotypes 3, 6A, and 19A in countries using lower-valent vaccines. Our objective was to estimate the clinical and economic benefit of replacing PCV10 with PCV13 in Colombia, Finland, and The Netherlands.MethodsCountry-specific databases, supplemented with published and unpublished data, informed the historical incidence of pneumococcal disease as well as direct and indirect medical costs. A decision-analytic forecasting model was applied, and both costs and outcomes were discounted. The observed invasive pneumococcal disease (IPD) trends from each country were used to forecast the future number of IPD cases given a PCV13 or PCV10 program.ResultsOver a 5-year time horizon, a switch to a PCV13 program was estimated to reduce overall IPD among 0–2?year olds by an incremental ??37.6% in Colombia, ??32.9% in Finland, and ??26% in The Netherlands, respectively, over PCV10. Adults??65 years experienced a comparable incremental decrease in overall IPD in Colombia (??32.2%), Finland (??15%), and The Netherlands (??3.7%). Serotypes 3, 6A, and 19A drove the incremental decrease in disease for PCV13 over PCV10 in both age groups. A PCV13 program was dominant in Colombia and Finland and cost-effective in The Netherlands at 1?×?GDP per capita (€34,054/QALY).ConclusionIn Colombia, Finland, and The Netherlands, countries with diverse epidemiologic and population distributions, switching from a PCV10 to PCV13 program would significantly reduce the burden of IPD in all three countries in as few as 5?years.